Cutaneous metastases develop in 4.5% of all patients with visceral malignant neoplasms. 1 The most frequent origins include breast, colon, and melanoma (in women) and lung, colon, and melanoma (in men). 2 The histologic diagnosis of cutaneous metastases often is fraught with difficulty because these lesions can mimic primary (adnexal) cutaneous adenocarcinomas. Furthermore, the elucidation of the origin of a cutaneous metastasis is difficult because metastatic cells often are less differentiated than the primary tumor. Cutaneous metastases are the first manifestation of the internal tumor in up to 21% of cases, 3 a fact making the histologic determination of the primary tumor more problematic. Immunohistochemical stains might aid the diagnosis by demonstrating tissuespecific antigens within tumor cells. Unfortunately, the list of such tumor-specific antigens is limited; it includes prostate-specific antigen for prostatic tumors 4 and thyroglobulin for carcinomas of the thyroid. 5 Furthermore, the predominant expression of the Tn vs the T (Thomsen-Friedenreich) antigen, 2 disaccharide cancerassociated antigens expressed in the skin by sebocytes and sweat gland cells and tumors arising therefrom, 6 favors the diagnosis of metastatic (over primary) epidermoid carcinoma 7 of the skin; however, to our knowledge, the expression of these antigens in primary skin adenocarcinomas has not been studied.
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Hepatocyte paraffin 1 (Hep Par 1) is a monoclonal antibody developed by Wennerberg et al 8 that recognizes a formalin-resistant antigen considered to be specific for hepatocellular mitochondria in normal and neoplastic hepatocytes; it can be used on paraffin-embedded tissue sections for confirmation of the diagnosis of hepatocellular carcinomas (HCCs) 9 and of cutaneous metastases arising therefrom. 10 Several recent studies suggested that this antigen also can be expressed by various nonhepatic tumors, such as urinary tumors 11 ; gastric and gallbladder hepatoid adenocarcinomas 12 ; cholangiocarcinomas 8, 13, 14 ; (adeno)carcinomas of the stomach, 8, 9, 15 pancreas, 8, 9 bowel, 13,15 lung, 9,13 esophagus, urinary bladder, 9 ovary, endocervix, and adrenal cortex; and yolk sac tumors. 13 As far as we know, Hep Par 1 has not been thoroughly studied for the diagnosis of cutaneous metastases. The aim of the present study was to assess the value of Hep Par 1 in the diagnosis of cutaneous metastatic tumors.
Materials and Methods

Tissue Specimens Studied
We studied 65 biopsy or excision specimens of cutaneous metastases retrieved retrospectively from the files of our laboratory. These specimens had been obtained during the past 15 years and were formalin fixed and paraffin embedded ❚Table 1❚. The diagnoses had been established by examination of H&E-stained sections, supplemented (when needed) with appropriate immunohistochemical stains (ie, for various keratins, epithelial membrane antigen, carcinoembryonic antigen, gross cystic disease fluid protein-15, Thomsen-Friedenreich and Tn antigens, S-100 protein, estrogen and progesterone receptors, and HER-2/neu). Clinical data (concerning the presence of a known primary tumor) were retrieved from the medical records of the patients.
Immunohistochemical Analysis
Immunohistochemical labeling was performed on deparaffinized and rehydrated 5-µm-thick sections. The Ventana ES automated aminoethyl carbazole (AEC) immunohistochemistry system (Ventana Medical Systems, Tucson, AZ) was used to study the reactivity of the IgG κ monoclonal antibody OCH1E5 (dilution 1:1,000; DAKO, Glostrup, Denmark), recognizing the Hep Par 1 antigen. Specimens of HCC served as positive control samples. Negative control samples were obtained by omitting the first-layer antibody and proved consistently negative.
Results
The results are summarized in Table 1 . The cutaneous metastases had been excised from 34 male and 31 female patients. The primary tumor sites, known in 51 cases, included 19 breast; 10 lung; 3 each of kidney and stomach; 2 each of liver, upper aerodigestive tract, colon, esophagus, oral cavity, and skin (squamous cell carcinoma and melanoma); and one each of larynx, small intestine, pancreas and uterus (leiomyosarcoma). In 14 cases the primary was unknown; of these, 3 were classified simply as adenocarcinomas and 2 as epidermoid carcinomas.
The expression of Hep Par 1 in HCC was visualized as coarse, diffuse, granular cytoplasmic staining within tumor cells. This pattern was considered specific. The same reactivity pattern was observed in both cases of cutaneous metastases of HCC, although the percentage of immunoreactive tumor cells varied between the 2 cases studied (15% in the first case; almost 100% in the second case) ❚Image 1❚. This specific pattern of immunoreactivity also was found in 5 of 10 metastases of bronchial adenocarcinomas. The percentage of Hep Par 1-expressing tumor cells was highly variable, ranging from 5% to 100% ❚Image 2❚. In 5 additional metastases (from the small intestine, colon, breast, and 2 of unknown origin) a weaker, diffuse, nongranular cytoplasmic labeling was observed, but this was considered nonspecific. The remaining cases of metastases were completely nonreactive with OCH1E5.
Discussion
Cutaneous metastases from internal organs usually can be classified histologically as adenocarcinomas, epidermoid (squamous cell) carcinomas, melanomas, or secondary localizations of hematopoietic malignant neoplasms. In the case of well-differentiated tumors, the origin of the primary tumor may be recognized by simple histologic examination, but for less differentiated tumors, the primary origin often is difficult or impossible to elucidate histologically, even though immunohistochemical stains can provide a gross characterization of the tumor as (adeno)carcinoma, melanoma, lymphoma, or sarcoma. The origin of the tumor can be shown confidently in the case of cells that express tumorspecific antigens, such as prostate-specific antigen for prostatic tumors and thyroglobulin for thyroid carcinomas. 16 Hep Par 1 is a mitochondrial antigen expressed in normal and neoplastic hepatocytes but absent from bile ducts and nonparenchymal liver cells. It is recognized by the OCH1E5 monoclonal antibody, which produces a characteristic diffuse cytoplasmic granular labeling of approximately 0.5 to 4 µm in size. 8 Hep Par 1 has been used for the differential diagnosis of various hepatic tumors, but has not been studied thoroughly for the diagnosis of cutaneous metastases.
Several studies have shown that the overall sensitivity of Hep Par 1 for HCCs is high, ranging from 79% to 99.7%. 8, 9, 13, 15, [17] [18] [19] [20] [21] [22] The specificity of Hep Par 1 for HCCs also has been found to be high (>90%), although it is not absolute, because some extrahepatic malignant neoplasms might contain a variable (usually low) percentage of Hep Par 1-positive cells. These tumors include the following: urinary 10 ; gastric and gallbladder hepatoid adenocarcinomas 11 ; cholangiocarcinomas 8, 13, 14 ; (adeno)carcinomas of the stomach, 8, 9, 15 pancreas, 8, 9 bowel, 13,15 lung, 8, 13 esophagus, urinary bladder, 9 ovary, endocervix, and adrenal cortex; and yolk sac tumors. 13 When specifically mentioned, the reactivity pattern of Hep Par 1 on extrahepatic malignant neoplasms was reported to be indistinguishable from that observed on normal and neoplastic hepatocytes, ie, granular cytoplasmic. 12, 15 Therefore, for the differential diagnosis of liver tumors, the use of additional markers has been recommended to increase the accuracy of the pathologic diagnosis. 23 Our study shows that Hep Par 1 can be expressed with 2 different labeling patterns on cutaneous metastases. The first pattern, apparently undescribed so far, is a nonspecific pattern and manifests as diffuse, weak cytoplasmic staining. This is easily recognized and differentiated from the specific, coarse, granular, cytoplasmic labeling and should not be a source of diagnostic confusion, provided one is aware of the specific aspect of Hep Par 1 immunoreactivity. However, our results show that specific Hep Par 1 expression can be observed in 50% of cutaneous metastases of lung adenocarcinomas. This expression is indistinguishable from that observed in HCC and cutaneous metastases originating therefrom, both in appearance and the percentage of labeled tumor cells. The expression of Hep Par 1 in cutaneous metastases of pulmonary carcinomas is in keeping with previous data from the literature, showing that up to 28% of cases of primary lung adenocarcinomas express Hep Par 1. 9, 13 On the other hand, we found no cases of cutaneous metastases of carcinomas of the esophagus, stomach, pancreas, or bowel immunoreactive for Hep Par 1, despite the fact that the corresponding primary tumors can express this marker to various extents. 8, 9, 13, 15 The limited number of metastatic cases included in our study most likely accounts for this finding.
We consider Hep Par 1 an interesting immunohistochemical marker for the diagnosis of cutaneous metastases of HCC. However, its specificity is not absolute, because this antigen can be expressed by a considerable proportion (up to 50%) of metastatic lung adenocarcinoma cases. The finding of Hep Par 1 expression in a cutaneous metastatic tumor should not be considered synonymous with a hepatic origin, because it also is consistent with (at least) a pulmonary origin. In case of doubt, additional hepatocyte markers should be used (such as α fetoprotein, carcinoembryonic antigen, or albumin in situ hybridization) to increase the specificity of diagnosis.
Note: After this article was accepted for publication, we encountered a case of cutaneous metastasis of breast adenocarcinoma showing specific Hep Par 1 immunoreactivity in 10% of tumor cells.
